Literature DB >> 25589397

Mutations in Bruton's tyrosine kinase impair IgA responses.

Noriko Mitsuiki1, Xi Yang, Sophinus J W Bartol, Christina Grosserichter-Wagener, Yoshiyuki Kosaka, Hidetoshi Takada, Kohsuke Imai, Hirokazu Kanegane, Shuki Mizutani, Mirjam van der Burg, Menno C van Zelm, Osamu Ohara, Tomohiro Morio.   

Abstract

X-linked agammaglobulinemia (XLA) is a primary immunodeficiency caused by mutations in Bruton's tyrosine kinase (BTK), and is characterized by markedly decreased numbers of blood B cells and an absence of all immunoglobulin isotypes. We performed whole exome sequencing in a male pediatric patient with dysgammaglobulinemia with IgA deficiency. Genetic analysis revealed a BTK missense mutation (Thr316Ala). To investigate whether a BTK mutation underlay this antibody deficiency with marked decrease of IgA in this patient, we performed functional analyses of B cells and phagocytes, and molecular analyses of somatic hypermutation and class switch recombination. The BTK missense mutation resulted in B cells with reduced BTK and high IgM expression. Equal proportions of CD19(low) and CD19(normal) fractions were observed, and both included naïve and memory B cells. Calcium influx and phospholipase Cγ2 phosphorylation upon IgM stimulation were marginally impaired in CD19(low), but not in CD19(+) B cells. Similar to XLA patients, IgA transcripts showed low SHM levels, whereas IgG transcripts were hardly affected. Our analyses suggest that the BTK mutation likely underlies the disease in this case, and that hypomorphic BTK mutations can result in normal circulating B cell numbers, but specifically impair IgA responses.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25589397     DOI: 10.1007/s12185-015-1732-1

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  44 in total

Review 1.  The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective.

Authors:  A B Satterthwaite; O N Witte
Journal:  Immunol Rev       Date:  2000-06       Impact factor: 12.988

2.  Reference values for B cell subpopulations from infancy to adulthood.

Authors:  H Morbach; E M Eichhorn; J G Liese; H J Girschick
Journal:  Clin Exp Immunol       Date:  2010-09-20       Impact factor: 4.330

Review 3.  Genetic analysis of patients with defects in early B-cell development.

Authors:  Mary Ellen Conley; Arnon Broides; Vivian Hernandez-Trujillo; Vanessa Howard; Hirokazu Kanegane; Toshio Miyawaki; Sheila A Shurtleff
Journal:  Immunol Rev       Date:  2005-02       Impact factor: 12.988

Review 4.  Molecular defects in T- and B-cell primary immunodeficiency diseases.

Authors:  Charlotte Cunningham-Rundles; Prashant P Ponda
Journal:  Nat Rev Immunol       Date:  2005-11       Impact factor: 53.106

Review 5.  Diagnosis and evaluation of primary panhypogammaglobulinemia: a molecular and genetic challenge.

Authors:  Maaz S Mohiuddin; Jordan K Abbott; Nicholas Hubbard; Troy R Torgerson; Hans D Ochs; Erwin W Gelfand
Journal:  J Allergy Clin Immunol       Date:  2013-06       Impact factor: 10.793

6.  Human CD19 and CD40L deficiencies impair antibody selection and differentially affect somatic hypermutation.

Authors:  Menno C van Zelm; Sophinus J W Bartol; Gertjan J Driessen; Françoise Mascart; Ismail Reisli; Jose L Franco; Beata Wolska-Kusnierz; Hirokazu Kanegane; Louis Boon; Jacques J M van Dongen; Mirjam van der Burg
Journal:  J Allergy Clin Immunol       Date:  2014-01-11       Impact factor: 10.793

7.  CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency.

Authors:  Menno C van Zelm; Julie Smet; Brigitte Adams; Françoise Mascart; Liliane Schandené; Françoise Janssen; Alina Ferster; Chiung-Chi Kuo; Shoshana Levy; Jacques J M van Dongen; Mirjam van der Burg
Journal:  J Clin Invest       Date:  2010-03-08       Impact factor: 14.808

8.  Agammaglobulinemia associated with BCR⁻ B cells and enhanced expression of CD19.

Authors:  A Kerry Dobbs; Amma Bosompem; Elaine Coustan-Smith; Gayle Tyerman; Frank T Saulsbury; Mary Ellen Conley
Journal:  Blood       Date:  2011-06-21       Impact factor: 22.113

9.  X-linked agammaglobulinemia in a 10-year-old boy with a novel non-invariant splice-site mutation in Btk gene.

Authors:  Kota Maekawa; Masafumi Yamada; Yuka Okura; Yasumasa Sato; Yutaka Yamada; Nobuaki Kawamura; Tadashi Ariga
Journal:  Blood Cells Mol Dis       Date:  2010-02-01       Impact factor: 3.039

10.  Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine kinase.

Authors:  Sarah L Doyle; Caroline A Jefferies; Con Feighery; Luke A J O'Neill
Journal:  J Biol Chem       Date:  2007-10-11       Impact factor: 5.157

View more
  6 in total

1.  B cell repertoire in patients with a novel BTK mutation: expanding the spectrum of atypical X-linked agammaglobulinemia.

Authors:  Yu Nee Lee; Amit Nahum; Ori Toker; Arnon Broides; Atar Lev; Amos J Simon; Orli Megged; Oded Shamriz; Yuval Tal; Raz Somech
Journal:  Immunol Res       Date:  2022-01-10       Impact factor: 2.829

2.  Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy.

Authors:  Simon Schliffke; Mariela Sivina; Ekaterina Kim; Lisa von Wenserski; Benjamin Thiele; Nuray Akyüz; Clemens Falker-Gieske; Donjete Statovci; Anna Oberle; Toni Thenhausen; Artus Krohn-Grimberghe; Carsten Bokemeyer; Nitin Jain; Zeev Estrov; Alessandra Ferrajoli; William Wierda; Michael Keating; Jan A Burger; Mascha Binder
Journal:  Oncoimmunology       Date:  2018-01-15       Impact factor: 8.110

3.  Bruton's tyrosine kinase regulates gut immune homeostasis through attenuating Th1 response.

Authors:  Di Guan; Zixi Wang; Jianxin Huo; Shengli Xu; Kong-Peng Lam
Journal:  Cell Death Dis       Date:  2021-04-30       Impact factor: 8.469

4.  Hypomorphic Mutations in the BCR Signalosome Lead to Selective Immunoglobulin M Deficiency and Impaired B-cell Homeostasis.

Authors:  Christoph B Geier; Kai M T Sauerwein; Alexander Leiss-Piller; Isabella Zmek; Michael B Fischer; Martha M Eibl; Hermann M Wolf
Journal:  Front Immunol       Date:  2018-12-18       Impact factor: 7.561

5.  Presentation of a case of Bruton type primary agammaglobulinemia in Guinea.

Authors:  Kaba Condé; Hugues Ghislain Atakla; Mamadou Ciré Barry; Mohamed Lamine Condé; Malé Doré
Journal:  Pan Afr Med J       Date:  2020-08-31

Review 6.  Targeting BTK Signaling in the Microenvironment of Solid Tumors as a Feasible Cancer Therapy Option.

Authors:  Justin K Messex; Geou-Yarh Liou
Journal:  Cancers (Basel)       Date:  2021-05-03       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.